Developing “acoustic beads” for advanced rare and complex cell sorting in flow processes

This strategic partnership is set to explore the development of next-generation acoustic microspheres as an alternative to conventional magnetic beads for rare and complex cell sorting and separation in flow-based applications. 

This collaboration brings together Aenitis' proprietary acoustophoresis technology and Bracco's expertise in functionalised microsystems to focus on rare and complex cell sorting, a critical step in advancing cell therapy and biomanufacturing. Current methods, such as magnetic bead-based separation, are hindered by high costs, cell handling and washing issues, and scalability challenges. Acoustic microspheres offer a game-changing solution that combines precision with safety, efficiency, and cost-effectiveness.  

According to the collaborating companies, the benefits of acoustic microspheres include high biocompatibility, scalability and speed, greater cost-effectiveness and immense regulatory potential. “Acoustic microspheres are more than an innovation - they represent a paradigm shift for the cell therapy and biomanufacturing industries,” said Emmanuel Vincent, CEO of Aenitis Technologies. “By combining our acoustophoresis platform with Bracco’s deep expertise, we aim to address key industry challenges in a sector with high demand for technological innovations in bioprocesses.” 

This partnership underscores Aenitis' mission to provide solutions for cell sorting and separation, contributing to the broader goal of making advanced therapies more accessible worldwide. “Bracco is thrilled to support this pioneering application of acoustic microspheres in cell manufacturing. With over 30 years of expertise in ultrasound contrast agents, Bracco is well-positioned to apply this knowledge combined with the Aenitis’ expertise to transform cell sorting technology" said Thierry Bettinger, Bracco Research Center Geneva Director. "It paves the way for new opportunities in both clinical and industrial applications, providing significant benefits to researchers, manufacturers, and patients globally.”

Both Bracco and Aenitis will participate at the JP Morgan Healthcare Conference 2025, in San Francisco, from 13 to 16 January 2025. This industry event will provide an opportunity to discuss this collaboration and explore its potential applications in biomanufacturing and advanced therapies. 

Source: Aenitis Technologies

08.01.2025

• cells (233)
• company (200)
• cooperation (348)

• Bracco Imaging SpA